Patents by Inventor Sibylle HESS

Sibylle HESS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth Differentiation Factor 15 as Biomarker for Metformin
    Publication number: 20240102093
    Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 28, 2024
    Applicants: Sanofi-Aventis Deutschland GmbH, McMaster University
    Inventors: Sibylle HESS, Thorsten SADOWSKI, Hertzel GERSTEIN, Guillaume PARE, Gregory STEINBERG
  • Growth differentiation factor 15 as biomarker for metformin
    Patent number: 11807905
    Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: November 7, 2023
    Assignees: Sanofi-Aventis Deutschland GmbH
    Inventors: Sibylle Hess, Thorsten Sadowski, Hertzel Gerstein, Guillaume Pare, Gregory Steinberg
  • Growth Differentiation Factor 15 as Biomarker for Metformin
    Publication number: 20210254156
    Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
    Type: Application
    Filed: March 11, 2021
    Publication date: August 19, 2021
    Applicants: Sanofi-Aventis Deutschland GmbH, McMaster University
    Inventors: Sibylle HESS, Thorsten SADOWSKI, Hertzel GERSTEIN, Guillaume PARE, Gregory STEINBERG
  • Growth differentiation factor 15 as biomarker for metformin
    Patent number: 10975434
    Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 13, 2021
    Assignees: Sanofi-Aventis Deutschland GmbH
    Inventors: Sibylle Hess, Thorsten Sadowski, Hertzel Gerstein, Guillaume Pare, Gregory Steinberg
  • Pharmaceutical Composition for Use in the Treatment of a Neurodegenerative Disease
    Publication number: 20190070265
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: April 25, 2018
    Publication date: March 7, 2019
    Inventors: Sibylle Hess, Christian Hölscher
  • Growth Differentiation Factor 15 as Biomarker for Metformin
    Publication number: 20190002977
    Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 3, 2019
    Inventors: Sibylle HESS, Thorsten SADOWSKI, Hertzel GERSTEIN, Guillaume PARE, Gregory STEINBERG
  • Pharmaceutical composition for use in the treatment of a neurodegenerative disease
    Patent number: 9987332
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: June 5, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sibylle Hess, Christian Hölscher
  • PREDICTING RAPID DECLINE IN RENAL FUNCTION IN DIABETES
    Publication number: 20170115310
    Abstract: Methods of predicting rapid decline in renal function in diabetes employing panels of biomarkers. The methods are useful for predicting risk of decline of renal function in individual subject and also for selecting subjects for clinical trials.
    Type: Application
    Filed: March 18, 2015
    Publication date: April 27, 2017
    Inventors: Helen COLHOUN, Helen LOOKER, Paul MCKEIGUE, Marco COLUMBO, David DUNGER, Neil DALTON, Mary Julia BROSNAN, Everson NOGOCEKE, Felix AGAKOV, Sibylle HESS
  • PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
    Publication number: 20160354445
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN
  • Pharmaceutical composition for use in the treatment of a neurodegenerative disease
    Patent number: 9364519
    Abstract: The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 14, 2016
    Assignees: SANOFI-AVENTIS DEUTSCHLAND GMBH, UNIVERSITY OF ULSTER
    Inventors: Sibylle Hess, Christian Hoelscher, Andrees Boehme, Agnes Menut, Laurent Pradier, Veronique Taupin
  • PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
    Publication number: 20130116179
    Abstract: The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
    Type: Application
    Filed: September 4, 2012
    Publication date: May 9, 2013
    Applicants: UNIVERSITY OF ULSTER, SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sibylle HESS, Christian HOELSCHER, Andrees BOEHME, Agnes MENUT, Laurent PRADIER, Veronique TAUPIN